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ABSTRACT
Background Animal studies indicate a potential 
protective role of antidepressant medication (ADM) in 
models of colitis but the effect of their use in humans with 
ulcerative colitis (UC) remains unclear.
Objective To study the relationship between ADM use and 
corticosteroid dependency in UC.
Design Using the Clinical Practice Research Datalink 
we identified patients diagnosed with UC between 
2005 and 2016. We grouped patients according to 
serotonin selective reuptake inhibitor (SSRI) and tricyclic 
antidepressant (TCA) exposure in the 3 years following 
diagnosis: ‘continuous users’, ‘intermittent users’ and 
‘non- users’. We used logistic regression to estimate the 
adjusted risk of corticosteroid dependency between ADM 
exposure groups.
Results We identified 6373 patients with UC. Five 
thousand two hundred and thirty (82%) use no ADMs, 627 
(10%) were intermittent SSRI users and 282 (4%) were 
continuous SSRI users, 246 (4%) were intermittent TCA 
users and 63 (1%) were continuous TCA users.
Corticosteroid dependency was more frequent in 
continuous SSRI and TCA users compared with non- 
users (19% vs 24% vs 14%, respectively, χ2 p=0.002). 
Intermittent SSRI and TCA users had similar risks of 
developing corticosteroid dependency to non- users (SSRI: 
OR 1.19, 95% CI 0.95 to 1.50, TCA: OR 1.14, 95% CI 0.78 
to 1.66). Continuous users of both SSRIs and TCAs had 
significantly higher risks of corticosteroid dependency 
compared with non- users (SSRI: OR 1.62, 95% CI 1.15 to 
2.27, TCA: OR 2.02, 95% CI 1.07 to 3.81).
Conclusions Continuous ADM exposure has no protective 
effect in routine clinical practice in UC and identifies a 
population of patients requiring more intensive medical 
therapy. ADM use is a flag for potentially worse clinical 
outcomes in UC.
INTRODUCTION
Antidepressant medications (ADMs) may 
have a role in reducing intestinal inflamma-
tion.1 However, the benefits of pharmaco-
logical treatment with ADMs in patients with 
inflammatory bowel disease (IBD) are poorly 
researched. Evidence from animal models 
of IBD indicate that ADMs can reduce intes-
tinal inflammation via modulation of neuro- 
humoral pathways.2–5 However, studies in 
humans are conflicting regarding any benefit 
of ADM on disease outcomes in IBD.6–10 A 
Cochrane review found no firm conclusions 
regarding the effects of ADMs in IBD could 
be drawn and further studies are required.11
A two- way relationship between psycholog-
ical stress and disease activity in ulcerative 
colitis (UC) is likely.12 It is hypothesised that 
Summary box
What is already known about this subject?
 ► Antidepressant medications (ADMs) are used fre-
quently in the inflammatory bowel disease popula-
tion. Animal studies have demonstrated a potential 
role of antidepressants to ameliorate inflammation 
in colitis. One study of people living with ulcerative 
colitis (UC) suggested steroid requirements were 
lower during periods of ADM use. However, other 
studies demonstrate comorbid anxiety and depres-
sion are associated with worse outcomes in UC. It is 
unclear where the balance of these factors lies with 
respect to ADM use in routine clinical practice in UC.
What are the new findings?
 ► This study found that continuous use of serotonin 
selective reuptake inhibitors (SSRIs) and tricyclic 
antidepressants (TCA) were both associated with a 
significant increase in the risk of corticosteroid de-
pendency compared with non- users (SSRI: OR 1.62, 
95% CI 1.15 to 2.27, TCA: OR 2.02, 95% CI 1.07 to 
3.81).
How might it impact on clinical practice in the 
foreseeable future?
 ► Continuous ADM exposure in routine clinical prac-
tice in UC identifies a population of patients requir-
ing more intensive medical therapy and is a flag for 
potentially worse clinical outcomes in UC.
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activation of the sympathetic autonomic nervous system 
due to stress leads to secretion of epinephrine and 
norepinephrine, which has been linked to activation of 
macrophages and mast cells, which may in turn increase 
bacterial adherence to gut mucosa.1 13 14 Furthermore, 
stress activates the hypothalamic pituitary adrenal axis, 
which can result in increased gut permeability and levels 
of glucocorticoids, which if prolonged may desensi-
tise glucocorticoid receptors, paradoxically leading to 
a proinflammatory state.1 15–17 Conversely, patients with 
IBD have significantly higher prevalence of mood disor-
ders and use of ADMs than matched controls,18–21 but it 
remains unclear what impact these drugs may have on 
disease activity when used in routine clinical practice. 
While these drugs may ameliorate gut inflammation 
through neuro- humoral pathways it is also possible their 
use to treat comorbid mood disorders maybe associated 
with poorer outcomes in IBD. It is known comorbid 
depression and anxiety are associated with unfavourable 
outcomes, not least increased mortality, for many chronic 
diseases including IBDs.22–26
In order to determine the balance of these factors, 
we therefore aimed to study the relationship between 
ADM use and disease activity, as evidenced by cortico-
steroid dependency as previously defined by the British 
Society of Gastroenterology and the European Crohn’s 
and Colitis organisation, using a previously characterised 
cohort of patients with UC from a nationally representa-
tive research database.27–29
METHODS
Study design and data source
Using the Clinical Practice Research Datalink (CPRD) 
we undertook a study of patients diagnosed with UC in 
the period 2005–2016. CPRD is among the largest and 
best validated primary care research databases world-
wide. It contains prospectively collected, patient- level, 
pseudonymised electronic health records derived from 
674 general practices and is representative of the UK 
population, covering 8% of the population.30 General 
practitioners use a clinical coding system (Read codes) 
to record diagnoses, symptoms and prescriptions, as 
part of routine clinical care. Data are audited to ensure 
accuracy and completeness. Participating practices need 
to achieve and maintain ‘up to standard’ (UTS) status 
to continue contributing to the dataset. CPRD has been 
extensively validated for population- based studies of both 
IBD and ADM use.31 32
Incident case definition
We defined incident UC cases as patients with a first ever 
diagnosis Read code for UC at least 1 year after regis-
tering with an ‘UTS’ practice for the period 1 January 
2005 to 31 December 2016 using a published and vali-
dated methodology by Lewis et al.31 We excluded patients 
if they had codes for both Crohn’s disease (CD) and UC, 
or indeterminate codes (eg, ‘non- specific colitis’).
Patients who had a comorbid condition other than UC 
that might require regular or prolonged steroid use, such 
as patients with polymyalgia rheumatic and asthma, were 
also excluded to avoid potential confounding for our 
primary outcome measure. Patients with previous organ 
transplants were also excluded because of the likely use 
of concurrent immunosuppressant and steroid medica-
tions in this group. Patients were followed up for 3 years 
after the date of UC diagnosis until study end- point, 
de- registration, or death.
We extracted data for the most commonly prescribed 
tricyclic antidepressants (TCAs) and serotonin selective 
reuptake inhibitors (SSRIs) during the study period: 
amitriptyline, dosulepin, escitalopram, sertraline, citalo-
pram, fluoxetine and paroxetine.33 In a preliminary anal-
ysis, we identified 170 000 ADM prescriptions among 
patients with IBD and calculated that the median ADM 
prescription length was 30 days (IQR 28–56). For the 
purposes of this study, we assumed that all ADM prescrip-
tions were 30 days in length.
We categorised individuals according to TCA and SSRI 
use. We adapted previously validated methods to define 
patients who were ‘continuous users’, namely those with 
repeat prescriptions with a gap of no greater than 60 
days between consecutive prescriptions in the first 3 years 
after UC diagnosis.34 We defined ‘intermittent users’, as 
patients who had at least one prescription of a TCA or 
SSRI in the first 3 years following UC diagnosis, but were 
not ‘continuous users’. Our comparator group was ‘non- 
users’; patients who had no prescriptions for ADMs in the 
first 3 years after diagnosis of UC.
Outcome measure
We determined the proportion of patients who devel-
oped corticosteroid dependency since it is associated 
with poorer outcomes in patients with UC.35 We used the 
European Crohn’s and Colitis Organisation and British 
Society of Gastroenterology guidelines criteria to identify 
patients with corticosteroid dependency.28 36 A patient was 
defined as ‘corticosteroid dependent’ if they had either a 
prescription for corticosteroids that lasted longer than 3 
months or required a repeat corticosteroid prescription 
within 3 months of stopping the previous corticosteroid 
course. We assumed that a corticosteroid course was 56 
days long as British Society of Gastroenterology guidance 
recommends a 6–8 weeks course and a recent UK wide 
survey has found >98% of prescribers taper corticoste-
roids over 8 weeks in UC.28
Covariates
We included covariates with known or likely associa-
tions with TCA and SSRI use and CS dependence. These 
comprised: sex, age category at UC diagnosis and era of 
UC diagnosis.
Younger age at diagnosis may be associated with poorer 
outcomes in UC including increased steroid use compared 
with older patient groups.37 Patients were subdivided into 
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three groups denoting their age at diagnosis (<17, 17–39 
and ≥40).
The introduction of new steroid- sparing treatments has 
resulted in changing patterns of steroid prescription for 
IBD.38 To control for this, the 12- year study period was 
divided into three periods of 4 years to adjust for the impact 
of era of UC diagnosis on our outcome measure. Era 1 
covered the period from 1 January 2005 to 31 December 
2008, era 2 from 1 January 2009 to 31 December 2012 and 
era 3 from 01 January 2013 to 31 December 2016.
Statistical analysis
Baseline characteristics of the treatment groups were 
summarised using frequencies and percentages.
We compared the proportion of patients meeting the 
definition of corticosteroid dependency over the 3- year 
period in each treatment group using the χ2 test.
We used a logistic regression model to estimate the OR 
of developing corticosteroid dependency within the first 
3 years of UC diagnosis given TCA and SSRI use, adjusting 
for sex, age at diagnosis, era of diagnosis. We adjusted the 
analysis for clustering effects to account for differences in 
prescribing patterns between contributing primary care 
practices.
We considered a p value of less than or equal to 0.05 to be 
statistically significant. All analyses were performed using 
STATA V.16 (Statacorp LP).
RESULTS
Over the study period of January 2005 to December 2016, 
we identified 6373 individuals with incident UC who had at 
least 3 years of follow- up. Five thousand two hundred and 
thirty (82%) had no prescriptions for either SSRIs or TCAs. 
Five thousand four hundred and sixty- four (85.7%) had 
no prescriptions for SSRIs and were classed as ‘SSRI non- 
users’, 627 (9.8%) were ‘intermittent SSRI users’ and 282 
(4.4%) were ‘continuous SSRI users’ (table 1). Of the 6373 
individuals with UC 246 (3.9%) were ‘intermittent TCA 
users’ and 63 (1%) were ‘continuous TCA users’ (table 2).
Patients with ‘continuous’ and ‘intermittent’ SSRI treat-
ment were more likely to be women and smokers compared 
with ‘non- users’ (table 1). 2.5% of the ‘’non- users’, 43.2% 
of the ‘intermittent SSRI users’ and 47.5% of ‘continuous 
SSRI users’ had prior SSRI treatment, respectively in the 6 
months before IBD diagnosis.
SSRIs and steroid dependency
The proportion of individuals with UC who developed 
corticosteroid dependency within 3 years was similar in 
Table 1 Baseline characteristics of ulcerative colitis 










Male sex 3091 (57%) 270 (43%) 128 (45%)
Age at diagnosis
  <17 years 199 (4%) 1 (0%) 0 (0%)
  17–40 years 1599 (29%) 203 (33%) 82 (29%)
  >40 years 3666 (67%) 419 (67%) 200 (71%)
Era of diagnosis
  2005–2008 2561 (47%) 269 (43%) 105 (37%)
  2009–2012 2117 (39%) 264 (42%) 118 (42%)
  2013–2016 786 (14%) 94 (15%) 59 (21%)
Smoker 431 (8%) 85 (14%) 36 (13%)
Tricyclic ADM use
  Non- users 5230 (96%) 566 (90%) 268 (95%)
  Intermittent 
users
190 (4%) 50 (8%) 6 (2%)
  Continuous 
users
44 (1%) 11 (2%) 8 (3%)
*Non- users defined as patients with no SSRI prescriptions in first 3 
years of diagnosis.
†Intermittent users defined as patients who received at least one 
SSRI prescription within the first 3 years of diagnosis but were not 
continuous users.
‡Continuous users defined as patients with consecutive SSRI 
prescriptions for first 3 years after diagnosis where the interval 
between SSRI prescription <90 days.
ADM, antidepressant medication; SSRI, serotonin selective reuptake 
inhibitor.
Table 2 Baseline characteristics of ulcerative colitis 










Male sex 3351 (55%) 112 (46%) 26 (41%)
Age at diagnosis
  <17 years 197 (3%) 0 (0%) 1 (2%)
  17–40 years 1778 (29%) 77 (31%) 14 (22%)
  >40 years 4089 (67%) 169 (69%) 48 (76%)
Era of diagnosis
  2005–2008 2970 (46%) 112 (46%) 33 (52%)
  2009–2012 2379 (39%) 98 (40%) 22 (35%)
  2013–2016 895 (15%) 36 (15%) 8 (13%)
Smoker 517 (9%) 28 (11%) 7 (11%)
SSRI use
  Non- users 5230 (86%) 190 (77%) 44 (70%)
  Intermittent 
users
566 (9%) 50 (20%) 11 (17%)
  Continuous 
users
268 (4%) 6 (2%) 8 (13%)
*Non- users defined as patients with no TCA prescriptions in first 3 
years of diagnosis.
†Intermittent users defined as patients who received at least one 
TCA prescriptions within the first 3 years of diagnosis but were not 
continuous users.
‡Continuous users defined as patients with consecutive TCA 
prescriptions for first 3 years after diagnosis where the interval 
between TCA prescription <90 days.
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intermittent SSRI users and non- SSRI users (14.8% vs 
13.6%, p=0.38). However significantly more ‘continuous 
SSRI users’ developed corticosteroid dependency than 
non- SSRI users (18.8% vs 13.6%, p=0.01).
Intermittent SSRI use was associated with a similar 
adjusted risk of corticosteroid dependency compared with 
non- SSRI users (OR 1.19, 95% CI 0.95 to 1.50). However, 
continuous SSRI use was associated with a significantly 
higher adjusted risk of developing corticosteroid depen-
dency (OR 1.62, 95% CI 1.15 to 2.27, table 3) compared 
with non- SSRI users.
TCAs and steroid dependency
The proportion of individuals with UC who developed 
corticosteroid dependency within 3 years was similar in 
intermittent TCA users and non- TCA users (14.6% vs 
13.8%, p=0.71). However, significantly more continuous 
TCA users developed corticosteroid dependency than 
non- TCA users (23.8% vs 13.8%, p=0.02).
Intermittent TCA use was associated with a similar 
adjusted risk of corticosteroid dependency compared with 
non- TCA users (OR 1.14, 95% CI 0.78 to 1.66). However, 
continuous TCA use was associated with a significantly 
higher adjusted risk of developing corticosteroid depen-
dency (OR 2.02, 95% CI 1.07 to 3.81—table 3) compared 
with non- TCA users.
DISCUSSION
Key findings
In this large nationally representative cross- sectional study 
of over 6000 patients with UC, we demonstrated contin-
uous SSRI and TCA use are both associated with a signifi-
cantly increased risk of corticosteroid dependency. Our 
findings indicate that concurrent use of ADM in routine 
clinical practice identifies a population of patients with 
UC requiring more intensive medical therapy.
Findings in relation to other studies
We report a prevalence of ADM use of 23.1% among 
patients with UC in this nationally representative cohort. 
This is in keeping with previous studies which report a 
prevalence of ADM use of 24%–28%.20 39 40 Our findings 
suggest that ADM use in routine clinical practice is associ-
ated with a more severe disease course in UC, manifest as 
an increased risk of corticosteroid dependency.
Research investigating the impact of ADMs on outcomes 
in IBD is limited and reported findings are mixed and 
conflicting. Some studies have suggested ADM use may 
be associated with reduced disease activity in IBD.41 A 
study of 28 patients with UC examined steroid use in the 
year before and the year after ADM use.6 Among patients 
who had received an ADM—steroid prescriptions, disease 
relapses and endoscopic procedures were significantly 
less frequent in the year after treatment with ADM.
A retrospective cohort study examined clinical 
outcomes in patients with IBD given their exposure to 
ADMs.40 The authors found a lower adjusted incidence 
of initiating corticosteroids during periods of ADM 
exposure compared with non- exposure. The disparity 
with our findings is likely because we chose not to adjust 
for treatment with an ADM before UC diagnosis because 
of significant collinearity between this and ADM use after 
diagnosis.
To date, one randomised controlled trial has been 
conducted assessing the impact of ADMs on disease activity 
in patients with UC. Daghaghzadeh et al randomised 44 
patients with depression and either CD or UC, to either 
Table 3 Logistic regression for risk of corticosteroid 
dependency within 3 years of diagnosis among patients with 
UC
Unadjusted n=6373 Adjusted n=6373
OR 95% CI OR 95% CI
Sex
  Female 1 – 1 –
  Male 1.25 1.09 to 1.44 1.29 1.12 to 1.48
Age at diagnosis
  <17 2.15 1.54 to 2.99 2.15 1.54 to 3.01
  17–40 1 – 1 –
  >40 0.74 0.63 to 0.86 0.72 0.61 to 0.84
Era of diagnosis
  2005–2008 1 – 1 –
  2009–2012 0.99 0.84 to 1.16 0.97 0.82 to 1.14
  2013–2016 0.85 0.68 to 1.06 0.81 0.65 to 1.01
Smoking status
  Non- 
Smoker
1 – 1 –
  Smoker 0.90 0.79 to 1.03 0.89 0.78 to 1.01
TCA exposure*
  Non- users 1 – 1 –
  Intermittent 
users
1.07 0.74 to 1.55 1.14 0.78 to 1.66
  Continuous 
users
1.95 1.06 to 3.60 2.02 1.07 to 3.81
SSRI exposure†
  Non- users 1 – 1 –
  Intermittent 
users
1.11 0.88 to 1.39 1.19 0.95 to 1.50
  Continuous 
users
1.47 1.06 to 2.05 1.62 1.15 to 2.27
Statistically significant results in bold.
*Non- users defined as patients with no TCA prescriptions in first 
3 years of diagnosis. Intermittent users defined as patients who 
received at least one TCA prescriptions within the first 3 years of 
diagnosis but were not continuous users. Continuous users defined 
as patients with consecutive TCA prescriptions for first 3 years after 
diagnosis where the interval between TCA prescription <90 days.
†Non- users defined as patients with no SSRI prescriptions in first 
3 years of diagnosis. Intermittent users defined as patients who 
received at least one SSRI prescriptions within the first 3 years of 
diagnosis but were not continuous users. Continuous users defined 
as patients with consecutive SSRI prescriptions for first 3 years after 
diagnosis where the interval between antidepressant medication 
prescription <90 days.
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic 
antidepressant; UC, ulcerative colitis.
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12 weeks of duloxetine or placebo.8 Those in the treat-
ment arm reported experiencing significantly fewer 
symptoms, though this may have represented a reduc-
tion in functional gastrointestinal symptoms rather than 
reduced organic disease activity.42 43 A study by Sexton et 
al supports this, finding that ‘perceived stress’ is associ-
ated with IBD symptoms but not intestinal inflammation 
as determined by faecal calprotectin measurement.44
Chojnacki et al conducted a non- randomised trial 
which found a reduction in Mayo Clinic Disease Activity 
Index scores among individuals treated with tianeptine 
compared with placebo. Fewer patients in the treatment 
arm had a relapse of their UC than those on placebo 
(0/30 vs 3/30, respectively) however given the small 
numbers in both arms these findings should be inter-
preted with caution.10
Although there is some evidence from previous studies 
that both TCAs2 4 and SSRIs3 may ameliorate colitis, our 
findings suggest this may be outweighed by the asso-
ciation between a more severe UC disease process and 
depression.18 45 It is possible a bi- directional relationship 
between psychological comorbidity and IBD disease 
activity exists. A recent study by Gracie et al found base-
line anxiety, but not depression, in quiescent IBD was 
associated with a subsequent increased need for steroids, 
and importantly also observed active IBD, as defined by a 
raised calprotectin, was associated with onset of anxiety, 
highlighting the bi- directional interaction.46
Strengths and limitations
In this large population- based study, we used a validated 
research database representative of the general UK 
population making it less likely to be affected by referral 
centre bias. We modelled both our treatment groups and 
outcome on previously published work from CPRD, and 
our regression models included adjustments for demo-
graphic and clinical covariates.
There are limitations to the study design. CPRD 
contains data on all prescriptions in primary care. 
However, it does not capture corticosteroid prescriptions 
in secondary care meaning our study may have underesti-
mated corticosteroid use in some individuals.
Steroid dependency is a surrogate marker of disease 
severity. However, data on mucosal inflammation, disease 
extent and inflammatory markers such as faecal calpro-
tectin were not available for analysis. It is therefore 
possible some corticosteroids prescriptions were inap-
propriate, as individuals may have had functional symp-
toms rather than active UC. Although objective markers 
of disease activity were not available for analysis in this 
study, it is likely the clinicians prescribing corticosteroids 
would have had access to at least some of these. Some 
individuals may have developed corticosteroid depen-
dency as a consequence of failure to escalate to thiopu-
rine or biological therapies, which we were unable to 
account for in this study.47
We extracted prescription data for TCA and SSRI 
antidepressant medications. We acknowledge a small 
minority of patients may have been prescribed alternative 
ADMs not captured in this study. We did not analyse indi-
vidual dose ranges of ADMs although we have previously 
established 83% of amitriptyline prescriptions in this 
population are issued at a dose of 30 mg or less per day. 
We also developed a model based on published research 
to define patients considered as having ‘intermittent’ 
and ‘continuous’ ADM use, allowing us to explore a 
dose–response relationship.34
We were not able to identify the specific indication for 
ADM prescription. However, in a cohort of primary care 
patients in the UK, contemporary with our study period, 
the indication for the majority of ADM prescriptions was 
either depression or anxiety.48 Given a significant propor-
tion of TCA prescriptions were for low dose amitriptyline, 
it is likely in many cases TCAs were prescribed for other 
indications such as chronic pain, as higher doses are indi-
cated for depression and anxiety. Both SSRIs and TCAs 
can cause gastrointestinal symptoms as side- effects, which 
could be interpreted as symptoms of UC, potentially 
resulting in inappropriate corticosteroid prescription.49 
We also recognise the possibility that corticosteroid use 
itself may increase the risk of depression among patients 
with IBD,50 though their impact in this respect is usually 
short lived.51
Implications
Our findings indicate an association between ADM 
use and worse clinical outcomes in UC as evidenced by 
increased corticosteroid dependency, underscoring the 
possible bi- directional relationship between psychiatric 
comorbidity and poorer outcomes in UC. It is well estab-
lished that individuals with active UC are more likely 
to develop depression, but the converse may also be 
possible.18 This study reinforces the notion that manage-
ment of common comorbid mental health disorders 
needs to be integral to the management of patients with 
UC.
The use of ADMs in IBD is supported by both national 
and international guidelines,52 53 although the evidence 
base is limited and further work to evaluate treatment 
approaches for depression in IBD is required.
Gastroenterologists are reportedly poor at recognising 
concurrent psychiatric illnesses among their patients,54 
despite guidelines encouraging doctors to screen for 
these conditions.53 Continuous ADM use among patients 
with UC can be considered a surrogate marker for 
worse disease outcomes. Patients receiving regular ADM 
prescriptions should be recognised as individuals poten-
tially at risk of a more aggressive disease course, as well as 
those who may require additional psychological support.
Prescribers also need to be aware patients’ adherence 
to medications for UC may be reduced among individ-
uals receiving medications for depression.55 Further 
prospective studies are needed to assess the temporal 
relationship between mood disorders and IBD disease 
exacerbations. The neuro- immunomodulatory action of 
ADM on IBD disease activity using validated measures of 
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inflammation is yet to be determined, although the forth-
coming MODULATE trial may address the use of amitrip-
tyline in stable UC.
CONCLUSIONS
ADM use in routine clinical practice identifies a popu-
lation of patients with UC with worse clinical outcomes 
manifest as increased rates of corticosteroid dependency. 
Clinicians should consider ADM use a flag for potentially 
worse clinical outcomes in the natural history of UC.
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